GlassScriptPhysician profile
Kevin Pham
NPI 1477623635
$23,531.43
in general payments reported to CMS, 2019-2025
41 companies · $4,143 in 2025
The $4,143 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,542 · 2020: $3,109 · 2021: $2,820 · 2022: $2,799 · 2023: $3,430 · 2024: $3,689 · 2025: $4,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,143.52 |
| Education | $118.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,933.67 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $1,729.12 | 2019-2024 | Rayaldee |
| Akebia Therapeutics INC | $1,702.06 | 2019-2025 | Vafseo, Auryxia |
| Mallinckrodt Hospital Products INC. | $1,574.81 | 2020-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $1,461.41 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $1,418.44 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $1,126.08 | 2019-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $1,058.64 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $1,057.26 | 2019-2025 | Parsabiv, Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $936.56 | 2019-2023 | Krystexxa |
| Ardelyx, INC. | $688.56 | 2023-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $632.41 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $521.76 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $517.72 | 2020-2025 | Benlysta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $371.23 | 2022-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.